310 related articles for article (PubMed ID: 25154203)
1. [Fecal lactoferrin in identifying and management of inflammatory bowel disease].
Pac-Kozuchowska E; Krawiec P; Mroczkowska-Juchkiewicz A
Pol Merkur Lekarski; 2014 Jul; 37(217):61-4. PubMed ID: 25154203
[TBL] [Abstract][Full Text] [Related]
2. Clinical utility of calprotectin and lactoferrin as markers of inflammation in patients with inflammatory bowel disease.
Caccaro R; D'Incá R; Sturniolo GC
Expert Rev Clin Immunol; 2010 Jul; 6(4):551-8. PubMed ID: 20594128
[TBL] [Abstract][Full Text] [Related]
3. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices.
Langhorst J; Elsenbruch S; Koelzer J; Rueffer A; Michalsen A; Dobos GJ
Am J Gastroenterol; 2008 Jan; 103(1):162-9. PubMed ID: 17916108
[TBL] [Abstract][Full Text] [Related]
4. Review of fecal biomarkers in inflammatory bowel disease.
Sutherland AD; Gearry RB; Frizelle FA
Dis Colon Rectum; 2008 Aug; 51(8):1283-91. PubMed ID: 18543035
[TBL] [Abstract][Full Text] [Related]
5. Fecal leukocyte proteins in inflammatory bowel disease and irritable bowel syndrome.
Silberer H; Küppers B; Mickisch O; Baniewicz W; Drescher M; Traber L; Kempf A; Schmidt-Gayk H
Clin Lab; 2005; 51(3-4):117-26. PubMed ID: 15819166
[TBL] [Abstract][Full Text] [Related]
6. Fecal lactoferrin as a noninvasive biomarker in inflammatory bowel diseases.
Langhorst J; Boone J
Drugs Today (Barc); 2012 Feb; 48(2):149-61. PubMed ID: 22384454
[TBL] [Abstract][Full Text] [Related]
7. The use of fecal calprotectin and lactoferrin in patients with IBD. Review.
Stragier E; Van Assche G
Acta Gastroenterol Belg; 2013 Sep; 76(3):322-8. PubMed ID: 24261027
[TBL] [Abstract][Full Text] [Related]
8. Calprotectin and lactoferrin in the assessment of intestinal inflammation and organic disease.
D'Incà R; Dal Pont E; Di Leo V; Ferronato A; Fries W; Vettorato MG; Martines D; Sturniolo GC
Int J Colorectal Dis; 2007 Apr; 22(4):429-37. PubMed ID: 16838143
[TBL] [Abstract][Full Text] [Related]
9. Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome.
Kaiser T; Langhorst J; Wittkowski H; Becker K; Friedrich AW; Rueffer A; Dobos GJ; Roth J; Foell D
Gut; 2007 Dec; 56(12):1706-13. PubMed ID: 17675327
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic performance of rapid tests for detection of fecal calprotectin and lactoferrin and their ability to discriminate inflammatory from irritable bowel syndrome.
Otten CM; Kok L; Witteman BJ; Baumgarten R; Kampman E; Moons KG; de Wit NJ
Clin Chem Lab Med; 2008; 46(9):1275-80. PubMed ID: 18597588
[TBL] [Abstract][Full Text] [Related]
11. Diagnostics and prognostics of inflammatory bowel disease with fecal neutrophil-derived biomarkers calprotectin and lactoferrin.
Sipponen T
Dig Dis; 2013; 31(3-4):336-44. PubMed ID: 24246984
[TBL] [Abstract][Full Text] [Related]
12. [Indicators of inflammatory process in stool in diagnostics and monitoring of inflammatory bowel diseases].
Iwańczak B; Iwańczak F
Pol Merkur Lekarski; 2015 Dec; 39(234):389-92. PubMed ID: 26802694
[TBL] [Abstract][Full Text] [Related]
13. [Utility of fecal markers of inflammation in the diagnostics of inflammatory bowel diseases].
Borkowska A; Liberek A; Plata-Nazar K; Kamińiska B
Med Wieku Rozwoj; 2010; 14(1):37-41. PubMed ID: 20608427
[TBL] [Abstract][Full Text] [Related]
14. [Fecal Calprotectin in Inflammatory Bowel Disease].
Lee J
Korean J Gastroenterol; 2016 May; 67(5):233-7. PubMed ID: 27206433
[TBL] [Abstract][Full Text] [Related]
15. Prospective evaluation of faecal neutrophil-derived proteins in identifying intestinal inflammation: combination of parameters does not improve diagnostic accuracy of calprotectin.
Schröder O; Naumann M; Shastri Y; Povse N; Stein J
Aliment Pharmacol Ther; 2007 Oct; 26(7):1035-42. PubMed ID: 17877510
[TBL] [Abstract][Full Text] [Related]
16. FECAL CALPROTECTIN: levels for the ethiological diagnosis in Brazilian patients with gastrointestinal symptoms.
Kotze LM; Nisihara RM; Marion SB; Cavassani MF; Kotze PG
Arq Gastroenterol; 2015; 52(1):50-4. PubMed ID: 26017083
[TBL] [Abstract][Full Text] [Related]
17. Technology insight: calprotectin, lactoferrin and nitric oxide as novel markers of inflammatory bowel disease.
Lundberg JO; Hellström PM; Fagerhol MK; Weitzberg E; Roseth AG
Nat Clin Pract Gastroenterol Hepatol; 2005 Feb; 2(2):96-102. PubMed ID: 16265127
[TBL] [Abstract][Full Text] [Related]
18. Accuracy of four fecal assays in the diagnosis of colitis.
Schoepfer AM; Trummler M; Seeholzer P; Criblez DH; Seibold F
Dis Colon Rectum; 2007 Oct; 50(10):1697-706. PubMed ID: 17762964
[TBL] [Abstract][Full Text] [Related]
19. [Calprotectin: a fecal marker for diagnosis and follow-up in patients with chronic inflammatory bowel disease].
van den Bergh FA; Kolkman JJ; Russel MG; Vlaskamp RT; Vermes I
Ned Tijdschr Geneeskd; 2003 Nov; 147(48):2360-5. PubMed ID: 14677476
[TBL] [Abstract][Full Text] [Related]
20. [Fecal calprotectin: a diagnostic tool for inflammatory bowel disease].
Fraga M; Godat S; Nydegger A; Moradpour D; Schoepfer AM
Rev Med Suisse; 2012 Sep; 8(352):1669-70, 1672-3. PubMed ID: 22988727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]